Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: Correlation of molecular type and in vitro susceptibility

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 2, 2012, Pages 144-148

  Lockhart, Shawn R ^a   Iqbal, Naureen ^a   Bolden, Carol B ^a   DeBess, Emilio E ^b   Marsden Haug, Nicola ^c   Worhle, Ron ^c   Thakur, Rameshwari ^d   Harris, Julie R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Adesh Institute of Medical Sciences and Research   (India)

^c WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^d Adesh University   (India)

Author keywords

Cryptococcus gattii; Epidemiologic cutoff value; MIC; Susceptibility

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANALYTICAL PARAMETERS; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CRYPTOCOCCUS GATTII; EPIDEMIOLOGIC CUTOFF VALUE; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; STATISTICS, NONPARAMETRIC; TRIAZOLES;

EID: 84861186456     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.02.018     Document Type: Article

References (43)

1. Bovers M., Hagen F., Boekhout T. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Mycol 2008, 25:S4-S12.
2. Byrnes E.J., Bildfell R.J., Frank S.A., Mitchell T.G., Marr K.A., Heitman J. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis 2009, 199:1081-1086.
3. Byrnes E.J., Li W., Lewit Y., Ma H., Voelz K., Ren P., et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 2010, 6:e1000850.
4. Carriconde F., Gilgado F., Arthur I., Ellis D., Malik R., van de Wiele N., et al. Clonality and α-a recombination in the Australian Cryptococcus gattii VGII population-an emerging outbreak in Australia. PLoS One 2011, 6:e16936.
5. Centers for Disease Control and Prevention (CDC) Emergence of Cryptococcus gattii-Pacific Northwest, 2004-2010. Morb Mortal Wkly Rep 2010, 59:865-868.
6. Chandenier J., Adou-Bryn K.D., Douchet C, Sar B., Kombila M., Swinne D., et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004, 23:506-508.
7. Chen S., Sorrell T., Nimmo G., Speed B., Currie B., Ellis D., et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000, 31:499-508.
8. Chen Y.C., Chang S.C., Shih C.C., Hung C.C., Luhbd K.T., Pan Y.S., et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 2000, 36:175-183.
9. Chong H.S., Dagg R., Malik R., Chen S., Carter D. In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 2010, 48:4115-4120.
10. Chowdhary A., Randhawa H.S., Sundar G., Kathuria S., Prakash A., Khan Z., et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 2011, 60:961-967.
11. Clinical Laboratory Standards Institute M27-A3 Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard-third edition 2008, Clinical Laboratory Standards Institute, Wayne (Pa).
12. Dannaoui E., Abdul M., Arpin M., Michel-Nguyen A., Piens M.A., Favel A., et al. French Cryptococcosis Study Group Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006, 50:2464-2470.
13. Datta K., Jain N., Sethi S., Rattan A., Casadevall A., Banerjee U. Fluconazole and itraconazole susceptibilities of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India; a need for care. J Antimicrob Chemother 2003, 52:683-686.
14. Espinel-Ingroff A., Diekema D.J., Fothergill A., Johnson E., Pelaez T., Pfaller M.A., et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010, 48:3251-3257.
15. Fraser J.A., Giles S.S., Wenink E.C., Geunes-Boyer S.G., Wright J.R., Diezmann S., et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005, 437:1360-1364.
16. Gillece J.D., Schupp J.M., Balajee S.A., Harris J., Pearson T., Yan Y., et al. Whole genome sequence analysis of Cryptococcus gattii in the Pacific Northwest reveals unexpected diversity. PLoS. ONE. 2011, 6:e28550.
17. Gomez-Lopez A., Zaragoza O., Dos Anjos Martins M., Melhem M.C., Rodriguez-Tudela J.L., Cuenca-Estrella M. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 2008, 14:727-730.
18. Hagen F., Illnait-Zaragozi M.T., Bartlett K.H., Swinne D., Geertsen E., Klaassen C.H., et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 2010, 54:5139-5145.
19. Harris J.R., Lockhart S.R., Debess E., Marsden-Haug N., Goldoft M., Wohrle R., et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011, 53:1188-1195.
20. Heath C.H., Slavin M.A., Sorrell T.C., Handke R., Harun A., Phillips M., et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009, 15:689-693. Australian Scedosporium Study Group.
21. Iqbal N.J., Boey A., Park B.J., Brandt M.E. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods. Diagn Microbiol Infect Dis 2008, 62:348-350.
22. Iqbal N.J., DeBess E.E., Wohrle R., Sun B., Nett R.J., Ahlquist A.M., et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 2010, 48:539-544. Cryptococcus gattii Public Health Working Group.
23. Khan Z.U., Randhawa H.S., Kowshik T., Chowdhary A., Chandy R. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 2007, 60:312-316.
24. Kidd S.E., Hagen F., Tscharke R.L., Huynh M., Bartlett K.H., Fyfe M., et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004, 101:17258-17263.
25. Kwon-Chung K.J., Polacheck I., Bennett J.E. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982, 15:535-537.
26. Li S.S., Mody C.H. Cryptococcus. Proc Am Thorac Soc 2010, 7:186-196.
27. MacDougall L., Kidd S.E., Galanis E., Mak S., Leslie M.J., Cieslak P.R., et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007, 13:42-50.
28. Meyer W., Aanensen D.M., Boekhout T., Cogliati M., Diaz M.R., Esposto M.C., et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 2009, 12:1-14.
29. Meyer W., Castañeda A., Jackson S., Huynh M., Castañeda E. Molecular typing of Iberoamerican Cryptococcus neoformans isolates. Emerg Infect Dis 2003, 9:189-195. IberoAmerican Cryptococcal Study Group.
30. Morera-López Y., Torres-Rodríguez J.M., Jiménez-Cabello T., Baró-Tomás T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005, 43:505-510.
31. Ngamskulrungroj P., Gilgado F., Faganello J., Litvintseva A.P., Leal A.L., Tsui K.M., et al. Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS One 2009, 4:e5862.
32. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
33. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010, 13:180-195. CLSI Subcommittee for Antifungal Susceptibility Testing.
34. Pfaller M.A., Boyken L.B., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J Clin Microbiol 2011, 49:1274-1279.
35. Pfaller M.A., Castanheira M., Diekema D.J., Messer S.A., Jones R.N. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis 2011, 71:252-259.
36. Pfaller M.A., Castanheira M., Messer S.A., Moet G.J., Jones R.N. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011, 69:45-50.
37. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005, 43:2163-2167.
38. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Monzon A., Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008, 52:2468-2472.
39. Tay S.T., Tanty Haryanty T., Ng K.P., Rohani M.Y., Hamimah H. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 2006, 49:324-330.
40. Thompson G.R., Wiederhold N.P., Fothergill A.W., Vallor A.C., Wickes B.L., Patterson T.F. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009, 53:309-311.
41. Trilles L., Fernández-Torres B., Lazéra Mdos S., Wanke B., Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 2004, 42:4815-4817.
42. Trilles L., Meyer W., Wanke B., Guarro J., Lazéra M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol 2012, 50:328-332.
43. Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006, 12:418-425.